

Validation of the Microlife BP A3 PC upper arm blood pressure monitor in patients with diabetes mellitus according to the ANSI/AAMI/ISO 81060-2:2013 protocol

Beate Beime^a, Ralf Krüger^a, Gertrud Hammel^b, Peter Bramlage^a and Cornelia Deutsch^a

Objective The aim of the present study was to validate the blood pressure (BP) measurement device, Microlife BP A3 PC, in patients with diabetes mellitus, according to the ANSI/AAMI/ISO 81060-2:2013 protocol.

Patients and methods In 85 individuals aged 56–88 years, with predefined criteria for diabetes mellitus, BP measurements on the upper arm were performed alternately using the Microlife BP A3 PC and a standard mercury reference sphygmomanometer. A total of 333 comparisons were included for analysis.

Results The mean difference between the Microlife BP A3 PC and the reference was -1.5 ± 6.3 mmHg for systolic BP (SBP) and -1.3 ± 5.2 mmHg for diastolic BP (DBP) according to criterion 1 of the protocol. For SBP, a total of 209 of the 333 measurements were within the range of 5 mmHg (62.8%), whereas the corresponding numbers for DBP were 232 of 333 (69.7%). For criterion 2, the intraindividual differences for the test device and the reference were -1.50 ± 4.73 mmHg for SBP

and -1.30 ± 4.55 mmHg for DBP, thus being within the defined ranges provided by the protocol.

Conclusion The Microlife BP A3 PC fulfilled the requirements of criteria 1 and 2 of the ANSI/AAMI/ISO 81060-2:2013 protocol and can also be recommended for BP measurement in diabetic patients. *Blood Press Monit* 00:000–000 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Blood Pressure Monitoring 2017, 00:000–000

Keywords: Association for the Advancement of Medical Instrumentation, American National Standards Institute, blood pressure-measuring device, diabetes mellitus, ISO 81060-2:2013, Microlife BP A3 PC, validation

^aInstitute for Pharmacology and Preventive Medicine, Cloppenburg and ^bEstimate GmbH, Augsburg, Germany

Correspondence to Beate Beime, MSc, Institute for Pharmacology and Preventive Medicine, Bahnhofstrasse 20, 49661 Cloppenburg, Germany
Tel: +49 441 9251 7811; fax: +49 447 1850 3332;
e-mail: beate.beime@ippmed.de

Received 28 June 2017 Revised 6 October 2017 Accepted 13 October 2017